Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

amdipharm mercury australia pty ltd - imipramine hydrochloride, quantity: 25 mg - tablet, sugar coated - excipient ingredients: titanium dioxide; microcrystalline cellulose; colloidal anhydrous silica; sucrose; magnesium stearate; stearic acid; lactose monohydrate; hypromellose; maize starch; glycerol; povidone; iron oxide red; macrogol 8000; carnauba wax; purified talc; copovidone - major depression. nocturnal enuresis (from the age of 5 years onwards and provided the possibility of organic causes has first been excluded).

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

amdipharm mercury australia pty ltd - imipramine hydrochloride, quantity: 10 mg - tablet, sugar coated - excipient ingredients: macrogol 8000; povidone; stearic acid; hypromellose; purified talc; glycerol; magnesium stearate; titanium dioxide; maize starch; microcrystalline cellulose; iron oxide red; colloidal anhydrous silica; lactose monohydrate; sucrose; copovidone - major depression. nocturnal enuresis (from the age of 5 years onwards and provided the possibility of organic causes has first been excluded).

Estats Units - anglès - NLM (National Library of Medicine)

teva pharmaceuticals usa, inc. - calcitriol (unii: fxc9231jvh) (calcitriol - unii:fxc9231jvh) - calcitriol 0.25 ug - calcitriol is indicated in the management of secondary hyperparathyroidism and resultant metabolic bone disease in patients with moderate to severe chronic renal failure (ccr 15 to 55 ml/min) not yet on dialysis. in children, the creatinine clearance value must be corrected for a surface area of 1.73 square meters. a serum ipth level of ≥ 100 pg/ml is strongly suggestive of secondary hyperparathyroidism. calcitriol is indicated in the management of hypocalcemia and the resultant metabolic bone disease in patients undergoing chronic renal dialysis. in these patients, calcitriol administration enhances calcium absorption, reduces serum alkaline phosphatase levels, and may reduce elevated parathyroid hormone levels and the histological manifestations of osteitis fibrosa cystica and defective mineralization. calcitriol is also indicated in the management of hypocalcemia and its clinical manifestations in patients with postsurgical hypoparathyroidism, idiopathic hypoparathyroidism, and pseudohypoparathyroidism. c

Estats Units - anglès - NLM (National Library of Medicine)

physicians total care, inc. - calcitriol (unii: fxc9231jvh) (calcitriol - unii:fxc9231jvh) - calcitriol 0.25 ug - calcitriol is indicated in the management of secondary hyperparathyroidism and resultant metabolic bone disease in patients with moderate to severe chronic renal failure (ccr 15 to 55 ml/min) not yet on dialysis. in children, the creatinine clearance value must be corrected for a surface area of 1.73 square meters. a serum ipth level of ≥ 100 pg/ml is strongly suggestive of secondary hyperparathyroidism. calcitriol is indicated in the management of hypocalcemia and the resultant metabolic bone disease in patients undergoing chronic renal dialysis. in these patients, calcitriol administration enhances calcium absorption, reduces serum alkaline phosphatase levels, and may reduce elevated parathyroid hormone levels and the histological manifestations of osteitis fibrosa cystica and defective mineralization. calcitriol is also indicated in the management of hypocalcemia and its clinical manifestations in patients with postsurgical hypoparathyroidism, idiopathic hypoparathyroidism, and pseudohypoparat

Nova Zelanda - anglès - Ministry for Primary Industries

rainbow & brown limited - glyphosate - glyphosate 540 g/litre - herbicide

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - felodipine, quantity: 10 mg - tablet, modified release - excipient ingredients: sodium stearylfumarate; carnauba wax; hypromellose; aluminium sodium silicate; iron oxide red; titanium dioxide; hyprolose; lactose; iron oxide yellow; peg-40 hydrogenated castor oil; microcrystalline cellulose; macrogol 6000; propyl gallate - hypertension.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - felodipine, quantity: 10 mg - tablet, modified release - excipient ingredients: microcrystalline cellulose; titanium dioxide; peg-40 hydrogenated castor oil; propyl gallate; hyprolose; iron oxide red; hypromellose; macrogol 6000; iron oxide yellow; sodium stearylfumarate; aluminium sodium silicate; lactose; carnauba wax - hypertension.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - quinapril hydrochloride, quantity: 21.66 mg (equivalent: quinapril, qty 20 mg) - tablet, film coated - excipient ingredients: magnesium stearate; gelatin; lactose monohydrate; magnesium carbonate hydrate; crospovidone; candelilla wax; titanium dioxide; hypromellose; hyprolose; iron oxide red; macrogol 400 - hypertension. accupril is indicated for the treatment of hypertension. it may be used alone or in combination with thiazide diuretics. sufficient data have not been provided to support the use of accupril in renovascular hypertension. congestive heart failure. accupril is indicated as an adjunctive treatment of mild to moderate congestive heart failure when given concomitantly with a diuretic and/or cardiac glycoside.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - quinapril hydrochloride, quantity: 10.83 mg (equivalent: quinapril, qty 10 mg) - tablet, film coated - excipient ingredients: lactose monohydrate; candelilla wax; crospovidone; magnesium carbonate hydrate; magnesium stearate; gelatin; titanium dioxide; hypromellose; hyprolose; iron oxide red; macrogol 400 - hypertension. accupril is indicated for the treatment of hypertension. it may be used alone or in combination with thiazide diuretics. sufficient data have not been provided to support the use of accupril in renovascular hypertension. congestive heart failure. accupril is indicated as an adjunctive treatment of mild to moderate congestive heart failure when given concomitantly with a diuretic and/or cardiac glycoside.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - quinapril hydrochloride, quantity: 5.42 mg (equivalent: quinapril, qty 5 mg) - tablet, film coated - excipient ingredients: candelilla wax; lactose monohydrate; magnesium stearate; crospovidone; magnesium carbonate hydrate; gelatin; titanium dioxide; hypromellose; hyprolose; iron oxide red; macrogol 400 - hypertension. accupril is indicated for the treatment of hypertension. it may be used alone or in combination with thiazide diuretics. sufficient data have not been provided to support the use of accupril in renovascular hypertension. congestive heart failure. accupril is indicated as an adjunctive treatment of mild to moderate congestive heart failure when given concomitantly with a diuretic and/or cardiac glycoside.